Barclays lowered the firm’s price target on Regeneron (REGN) to $1,065 from $1,080 and keeps an Overweight rating on the shares post the Q3 report. The firm says recent pressure on Regeneron shares is overdone as it sees an overreaction to the Pavblu news, disappointing Q4 Eylea HD outlook, and lack of messaging around forward Eylea growth.
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron Pharmaceuticals Reports Strong Q3 2024 Results
- Regeneron files automatic mixed securities shelf
- Regeneron price target lowered to $1,215 from $1,260 at RBC Capital
- Regeneron price target lowered to $1,150 from $1,200 at Oppenheimer
- Morning Movers: Roblox surges and Estee Lauder sinks following earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
